Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study Genovese, M. C., Carlier, H., Erickson, J., Braun, D., Banerjee, S. WILEY-BLACKWELL. 2013: S188
View details for Web of Science ID 000325359201433